geoffrey modest medical blogs

  A recent Swiss cohort study confirmed prior studies finding increased weight gain and lipid changes with tenofovir alafenamide (TAF); this study assessed changes after having been switched from tenofovir disoproxil fumarate, TDF, to TAF (see   hiv TAF inc wt metab change AIM2021  in dropbox, or doi:10.7326/M20-4853 )   Details:  -- 4375 adults living with HIV who had been on TDF-containing regimens for 6 months or longer, comparing pre-vs post-switch to TAF vs those remaining on TDF, after 18 months. From January 2016 to August 2019 -- 5 University hospitals, affiliated hospitals, and private physicians in Switzerland participated -- median age 50, 26% female, 51% normal BMI, median CD4 count 650, median duration of ART 11 years, mean duration of TDF before the index visit 8 years, -- medical comorbidities: diabetes 5%, history of vascular disease 6%, smoker 37%, lipid-lowering therapy 15%, median weight 74 kg, median BMI 24, median HDL 50  mg/dL , median LDL 107  mg/dL , median trig

  A recent US real-world evaluation of the 2 mRNA vaccines was just published: see https://www.cdc.gov/mmwr/volumes/70/wr/pdfs/mm7013e3-H.pdf or   covid mrna effectiveness in HCWs MMWR2021 in the dropbox   -- Prospective data of cohorts of health care personnel, 1 st responders, and other essential and front-line workers in 8 US locations, from December 14, 202 0 to March 13, 2021. The CDC routinely tested for SARS-CoV-2  infection every week, regardless of symptom status, as well as at the onset of symptoms consistent with Covid-19     -- Phoenix, Tucson, Miami, Duluth, Portland (Oregon), Temple (Texas), Salt Lake City         -- of these, 53% were from the Arizona study sites     -- participants: physicians and primary health care personnel 21%, nurses and other allied health care personnel 34%, 1 st responders 22%, other essential and front-line workers 24%     -- 62% female, 72% aged 18 to 49, 86% white, 83% non-Hispanic, no chronic medical conditions in 69%     -

  The Agency for Healthcare Research and Quality (AHRQ) just published a living systematic review on cannabis and other cannabinoid treatments for chronic pain (see   https://effectivehealthcare.ahrq.gov/products/plant-based-chronic-pain-treatment/living-review#toc_js_2   for the webpage and   https://effectivehealthcare.ahrq.gov/sites/default/files/pdf/plant-based-chronic-pain-review-q2.pdf   for the document.). This is considered a “living” systematic review since it will be updated regularly with new published literature. So, I am including the 1 st   link which gets to the general webpage and has links to all of the recent (and future) analyses, and the 2 nd   link is to the most current PDF (February 2021 update). A 3 rd   update/progress report is scheduled for late May 2021   This review adds 6 additional RCTs to the prior report of 14 RCTs of cannabis-related products and 3 observational studies, for a total of 23 studies including both 7 RCTs on products that contained a combi